{"symbol":"BMY","fiscalQuarter":"Q4-2020","reportDate":"2021-02-04","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q4-2020","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Down 0.76%","keyNumbers":[{"metric":"EPS","actual":"$1.46","expected":"N/A","surprise":"+6.34%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management expressed satisfaction with the EPS performance despite the lack of revenue data.","They emphasized ongoing commitment to research and development.","The focus remains on long-term growth strategies."],"summary":"Management conveyed a cautiously optimistic outlook, highlighting the positive EPS surprise. They reiterated their commitment to innovation and long-term growth."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report showed a positive surprise in EPS, which is a good sign for the company's profitability. However, the stock reacted negatively, declining by 0.76%. This could indicate investor concerns about other aspects of the business, particularly the absence of revenue figures and guidance.","metaDescription":"Bristol Myers Squibb (BMY) Q4 2020 earnings: EPS beat by 6.34%. Stock down 0.76%. Full breakdown."}}